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Abstract
We assessed the prevalence, awareness, treatment and control of hypertension in patients
with moderate chronic kidney disease (CKD) under nephrological care in Germany. In the
German Chronic Kidney Disease (GCKD) study, 5217 patients under nephrology specialist
care were enrolled from 2010 to 2012 in a prospective observational cohort study. Inclusion
criteria were an estimated glomerular filtration rate (eGFR) of 30–60 mL/min/1.73 m2 or
overt proteinuria in the presence of an eGFR>60 mL/min/1.73 m2. Office blood pressure
was measured by trained study personnel in a standardized way and hypertension aware-
ness and medication were assessed during standardized interviews. Blood pressure was
considered as controlled if systolic < 140 and diastolic < 90 mmHg. In 5183 patients in
whom measurements were available, mean blood pressure was 139.5 ± 20.4 / 79.3 ± 11.8
mmHg; 4985 (96.2%) of the patients were hypertensive. Awareness and treatment rates
were > 90%. However, only 2456 (49.3%) of the hypertensive patients had controlled blood
pressure. About half (51.0%) of the patients with uncontrolled blood pressure met criteria for
resistant hypertension. Factors associated with better odds for controlled blood pressure in
multivariate analyses included younger age, female sex, higher income, low or absent pro-
teinuria, and use of certain classes of antihypertensive medication. We conclude that blood
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pressure control of CKD patients remains challenging even in the setting of nephrology spe-
cialist care, despite high rates of awareness and medication use.
Introduction
Chronic kidney disease (CKD) has been increasingly recognized as a global health burden [1,
2]. The prevalence of CKD is 10–15% in the general adult population in both high- and low-
income countries. Individuals with CKD are at risk for progressive loss of kidney function and
kidney failure requiring renal replacement therapy. In addition, the presence of CKD worsens
the prognosis of many non-renal diseases. In particular, CKD has been recognized as a major
cardiovascular risk factor [3].
Blood pressure control is considered a mainstay of CKD management, in order to alleviate
the progressive loss of kidney function, as well as to lower the risk of cardiovascular disease
[4]. The controversial discussion about optimal blood pressure targets in CKD patients [5, 6]
has recently been rekindled by the results of the SPRINT trial in which 28% of enrolled
patients had CKD [7]. Several authors now recommend to lower blood pressure goals in
patients with CKD [8, 9]. All recent guidelines developed prior to publication of the SPRINT
trial propose maintaining blood pressure at least below 140/90 mmHg in all CKD patients
[10–12]. For patients with CKD and proteinuria above 300 mg/L, most guidelines [10, 11] sug-
gest lower blood pressure targets, although the evidence supporting this suggestion is limited
[5, 6]. Despite these recommendations, studies from large population-based surveys and CKD
cohorts in the United States [13, 14] as well as from western European countries [15, 16] have
shown rather poor rates of blood pressure control.
We enrolled >5200 patients treated by nephrologists into the German Chronic Kidney Dis-
ease (GCKD) study, a long-term observational cohort study [17]. A cross-sectional overview of
patient characteristics at baseline [18] showed rather high blood pressure levels, despite the
fact that >80% of patients had been under nephrology specialist care for at least 1 year. To bet-
ter understand the limitations of blood pressure control in this population we have therefore
analyzed associations with comorbidities, sociodemographic factors, medication patterns and
the presence of resistant hypertension. Our results describe the diversity of blood pressure con-
trol and overall emphasize the need to alleviate the burden of hypertension in CKD patients.
Materials and methods
Study participants
The design of the study has been previously published in detail [17]. The GCKD study was reg-
istered in a national database of clinical studies (“Deutsches Register fu¨r Klinische Studien”,
DRKS 00003971), and was approved by the ethics committees of all participating centers
(Friedrich Alexander University of Erlangen-Nuremberg, University of Freiburg, Ludwig-
MaximiliansUniversity of Munich, University of Hannover, Charite´ –Universita¨tsmedizin
Berlin, University of Wu¨rzburg, University of Aachen, University of Jena, Heidelberg Univer-
sity). Caucasian patients could be included into the study if age was 18 to 74 years, and if they
met at least one of two criteria: a) an estimated glomerular filtration rate (eGFR) between 30
and 60 ml/min/1.73 m2 or b) manifest proteinuria (urinary protein/creatinine >500 mg/g or
equivalent) if eGFR was >60 ml/min/1.73 m2. Patients were not able to participate if they pre-
viously underwent solid organ or bone marrow transplantation, had suffered a malignancy,
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had advanced heart failure, were under legal attendance or not able to provide informed con-
sent. Written informed consent was obtained from all participants prior to their enrolment.
Examinations performed
The patients were examined by certified study nurses in the regional GCKD centers or in the
nephrology practices of the participating nephrologists. The training of study nurses included
the correct and standardized conduct of blood pressure measurements. Prior to the blood
pressure measurements, upper arm circumference was determined in order to use the correct
cuff size (small, medium, large and extra-large cuffs were available). Blood pressure was mea-
sured in a sitting position after 5 min of rest with an oscillometric device (Omron M5 Profes-
sional devices). Three measurements were taken in the presence of the study nurse (“observed
measurements”) with two minutes between each measurement. The mean of the three mea-
surements went into the current analysis. No specific instructions were given with regard to
caffeine or tobacco intake on the day of the study visit. In addition, detailed information on
the medical history and sociodemographic factors was obtained. Definitions of co-morbidities
etc. were used according to international standards [18]. Information on the precise type of
any medication (prescribed and over the counter) was collected, but dosage and intake sched-
ules were not recorded. Substances were classified using the WHO’s Anatomical Therapeutic
Chemical (ATC) classification (http://www.whocc.no/). For the purpose of our analysis, all
antihypertensive medications were grouped into the following 7 main categories: (1) inhibitors
of the renin-angiotensin system (RAS; comprising the 3 sub-categories ACE inhibitors, AT1
blockers, and renin inhibitors); (2) diuretics (comprising the 3 sub-categories thiazide diuret-
ics, loop diuretics, and potassium-sparing diuretics including aldosterone blockers), (3) beta
blockers, (4) central sympatholytic agents, (5) peripheral acting alpha-adrenergic antagonists,
(6) calcium channel blockers, and (7) other vasodilators. All data presented in this manuscript
(including all blood pressure data and all covariates) were taken from the GCKD baseline visit.
Definitions of hypertension, awareness, control, and resistant hypertension
Patients were considered “hypertensive” if the mean of the 3 blood pressure measurements
was 140 mmHg systolic, or 90 mmHg diastolic, or if any antihypertensive drug was cur-
rently prescribed. A hypertensive patient was defined as “aware” of hypertension if he or she
described him- or herself as hypertensive in the patient questionnaire during the interview.
The blood pressure was defined as “controlled” if the mean of 3 recordings yielded < 140
mmHg systolic and< 90 mmHg diastolic in a patient classified as hypertensive. A hyperten-
sive patient was considered to suffer from “resistant hypertension” if the mean of the 3 blood
pressure measurements was 140 mmHg systolic, or 90 mmHg diastolic, despite a current
medication with at least 3 different antihypertensive drugs, including a diuretic.
Statistical analysis
Data is described using means ± standard deviations (SD) for continuous variables and frequency
distributions with percentages for categorical variables. Odds ratios with 95% confidence intervals
were calculated to analyze the univariate associations (or lack thereof) of controlled blood pressure
with a number of factors, including antihypertensive medications (i.e., the groups described
above), age category (18-<45, 45-< 65 and65 years old), sex, marital status (single, mar-
ried, divorced/separated, widowed), education, gross yearly income, type of health insurance (stat-
utory or private), body mass index (underweight: BMI< 18.5; normal weight: BMI18.5 to<25;
overweight: BMI25 to<30; obesity: BMI30), smoking status (non-smoker, former smoker,
current smoker), self-reported ethanol intake, diabetes mellitus (absence or presence), previous
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cardiovascular, cerebrovascular or peripheral vascular disease, stratum of urine albumin-to-creati-
nine ratio (< 30 mg/g,30-<300 mg/g, 300 mg/g), and eGFR stratum (60,45-< 60,30-
<45,<30 ml/min/1.73m2) estimated according to the 4-variable Modification of Diet in Renal
Disease formula [19]. For multivariate analysis, adjusted odds ratios with 95% confidence intervals
for all factors were calculated using the coefficient estimates obtained from binary logistic regres-
sion. A p-value< 0.05 was considered significant. Calculations were carried out using SAS Ver-
sion 9.2 by SAS Institute Inc., Cary NC, USA.
Results
Blood pressure data were available for analysis from 5183 participants. Mean ± SD blood pres-
sure was 139.5 ± 20.4 / 79.3 ± 11.8 mmHg (N = 5183). The distribution of blood pressure levels
in the entire cohort is shown in Fig 1. Mean blood pressure levels for subgroups defined by
age, sex, eGFR stratum, proteinuria stratum and presence of diabetes are shown in Table 1. No
fewer than 4985 of 5183 (96.2%) met the criteria for hypertension.
In the univariate analysis, several factors were associated with the prevalence of hyperten-
sion but effects were rather small. For example, the prevalence rose with age from 91.6% in the
18–44 years group to 95.6% in the 45–64 years group and to 97.9% in the 65–74 years group.
Effects of similar size were observed for gender (93.6% in women vs. 97.9% in men), education,
income, eGFR and proteinuria stratum (higher prevalence in higher strata), body mass index,
presence of diabetes (98.0% vs. 93.6% in non-diabetic patients) or history of cardiovascular
disease. Remarkably, all subgroups in all analyses exhibited a prevalence of hypertension >
90% (except for two very small subgroups with< 100 participants: patients with gross yearly
income in excess of 100.000 €, and patients with underweight).
Disease awareness was high among hypertensive patients (4557 of 4985 hypertensive partic-
ipants, i.e. 94.1%). Fig 2 shows the awareness of hypertension according to control of hyper-
tension and medication pattern. Patients with uncontrolled hypertension, and patients
receiving multiple antihypertensive medications, had the highest rates of awareness. In con-
trast, hitherto untreated hypertensive patients (N = 127) with blood pressure levels 140
mmHg systolic or 90 mmHg diastolic exhibited low awareness.
Table 2 summarizes the utilization of different classes of antihypertensive medications. The
vast majority (97.4%, N = 4854) of the hypertensive patients received at least one antihyperten-
sive drug; only 127 patients had a blood pressure > 140/90 mmHg, but were not treated with
antihypertensive medication. Most hypertensive patients (80.4%, N = 4008) received some
form of combination therapy: Two (22.3%, N = 1111), three (23.3%, N = 1159), or more than
three (34.9%, N = 1738) different antihypertensive drugs.
The control of hypertension, however, was rather low, despite the high awareness and treat-
ment rates and the intense antihypertensive pharmacotherapy. Using the rather conservative
blood pressure target level of< 140 mmHg systolic and< 90 mmHg diastolic, no fewer than
2529 of 4985 hypertensive patients (50.7%) failed to reach target levels. In most cases, the sys-
tolic component of blood pressure was not controlled (Fig 3). Reducing systolic blood pressure
can be limited by the risk of a too low diastolic blood pressure. To assess the prevalence of very
low diastolic pressure levels in this group, we plotted the diastolic blood pressure levels of the
1596 patients with uncontrolled systolic but controlled diastolic blood pressure (Fig 4). How-
ever, only 230 patients in this group had a diastolic blood pressure < 70 mmHg, suggesting
that diastolic blood pressure level was not a main hurdle for intensification of blood pressure
lowering in most patients with isolated systolic hypertension. In fact, roughly half of them had
a diastolic blood pressure between 80 and 90 mmHg and a low diastolic blood pressure would
not have been a hindrance for further blood pressure lowering.
Blood pressure control in CKD
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In the univariate analysis (Table 3), several factors were associated with a lower odds ratio
for successful control of blood pressure: higher age, male sex, lower education, lower income,
higher BMI, higher ethanol intake, presence of diabetes mellitus or peripheral vascular disease,
higher strata of proteinuria and lower eGFR. In the multivariate analysis (Table 3), some fac-
tors remained significant, exhibiting clearly lower odds for control of blood pressure: higher
age (OR 0.532 (0.411–0.690) for age4565 versus1845 and OR 0.379 (0.285–0.505) for
age65 versus1845, P<0.0001), male sex (OR 1.424 (1.208–1.678), P<0.0001), lower
income (OR 1.273 (1.082–1.498) for annual gross income 25.000–50.000 € versus <25.000 €,
OR 1.286 (1.011–1.636) for 50.000–100.000 € versus<25.000 €, and OR 1.635 (0.968–2.762)
Fig 1. Frequency distribution of systolic (upper panel) and diastolic (lower panel) blood pressure in participants
of the GCKD study.
https://doi.org/10.1371/journal.pone.0202604.g001
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Table 1. Blood pressure levels and control of blood pressure according to demographic, biometric and other factors.
Patients number
(%)
SBP
(mmHg)
DBP
(mmHg)
Patients with Hypertension
(%)
Uncontrolled
(%)
Controlled
(%)
Entire cohort 5183 (100) 139.5 ± 20.4 79.3 ± 11.8 4985 (96.2) 2529 (48.8) 2456 (47.4)
Age (years)
18 - < 45 632 (12.2) 129.6 ± 15.2 81.3 ± 11.5 579 (11.2) 193 (3.7) 386 (7.4)
 45 - < 65 2134 (41.2) 138.1 ± 19.5 81.9 ± 11.5 2039 (39.3) 1008 (19.4) 1031 (19.9)
 65 2417 (46.6) 143.3 ± 21.2 76.4 ± 11.4 2367 (45.7) 1328 (25.6) 1039 (20.0)
Sex
Male 3115 (60.1) 141.7 ± 20.1 79.3 ± 11.9 3050 (58.8) 1662 (32.1) 1388 (26.8)
Female 2068 (39.9) 136.2 ± 20.3 79.2 ± 11.5 1935 (37.3) 867 (16.7) 1068 (20.6)
Diabetes mellitus
No 3345 (64.5) 138.1 ± 19.7 80.9 ± 11.4 3165 (61.1) 1544 (26.8) 835 (16.1)
Yes 1838 (35.5) 142.0 ± 21.3 76.3 ± 11.8 1820 (35.1) 985 (19.0) 1621 (31.3)
eGFR (ml/min/1.73m2)
 60 1115 (21.8) 136.4 ± 19.4 80.8 ± 10.9 1031 (20.1) 467 (9.1) 564 (11.0)
 45 - < 60 1708 (33.3) 140.4 ± 20.1 80.0 ± 11.5 1633 (31.9) 870 (17.0) 763 (14.9)
 30 - < 45 1846 (36.0) 140.3 ± 20.6 78.4 ± 12.0 1815 (35.4) 929 (18.1) 886 (17.3)
< 30 458 (8.9) 139.8 ± 21.9 76.5 ± 12.9 455 (8.9) 230 (4.5) 225 (4.4)
Albuminuria (mg/g)
< 30 2176 (42.7) 136.5 ± 19.2 77.2 ± 11.4 2046 (40.2) 932 (18.3) 1114 (21.9)
 30 - < 300 1485 (29.2) 140.3 ± 20.3 79.5 ± 11.9 1442 (28.3) 747 (14.7) 695 (23.6)
 300 1434 (28.1) 143.2 ± 21.4 82.2 ± 11.4 1412 (27.7) 804 (15.8) 608 (11.9)
Marital Status
Single 478 (9.2) 137.1 ± 20.4 81.1 ± 11.7 456 (8.8) 203 (3.9) 253 (4.9)
Married 3991 (77.0) 139.7 ± 20.0 79.1 ± 11.7 3841 (74.1) 1978 (38.2) 1863 (35.9)
Separated/
divorced
370 (7.1) 137.7 ± 22.0 80.6 ± 12.1 349 (6.7) 168 (3.2) 181 (3.5)
Widowed 344 (6.6) 142.4 ± 22.3 77.3 ± 12.2 339 (6.5) 180 (3.5) 159 (3.1)
Education Level
Low 2765 (53.4) 141.1 ± 20.9 78.4 ± 11.7 2699 (52.1) 1429 (27.6) 1270 (24.5)
Intermediate 1446 (27.9) 137.9 ± 19.7 80.2 ± 11.6 1364 (26.3) 660 (12.7) 704 (13.6)
High 868 (16.8) 137.3 ± 19.4 80.4 ± 12.0 821 (15.8) 392 (7.6) 429 (8.3)
other 104 (2.0) 138.0 ± 19.7 79.2 ± 11.3 101 (1.9) 48 (0.9) 53 (1.0)
Annual gross income
< 25.000 € 1766 (46.7) 141.6 ± 20.7 78.3 ± 11.8 1720 (45.4) 939 (24.8) 781 (20.6)
25.000–50.000€ 1404 (37.1) 138.0 ± 19.1 79.3 ± 11.2 1344 (35.5) 645 (17.0) 699 (18.5)
50.000–100.000€ 528 (14.0) 136.5 ± 19.4 81.4 ± 11.7 497 (13.1) 232 (6.1) 265 (7.0)
> 100.00€ 87 (2.3) 133.0 ± 16.2 80.7 ± 11.4 76 (2.0) 32 (0.8) 44 (1.2)
Insurance status
Statutory 4822 (93.0) 139.6 ± 20.3 79.2 ± 11.7 4639 (89.5) 2359 (45.5) 2280 (44.0)
Private 358 (6.9) 138.5 ± 20.3 80.1 ± 11.8 343 (6.6) 168 (3.2) 175 (3.4)
unkown 3 (0.1) 134.7 ± 19.9 83.0 ± 11.0 3 (0.1) 2 (0.1) 1 (0.1)
Body Mass Index
<18.5 32 (0.6) 124.1 ± 21.5 75.2 ± 14.1 24 (0.5) 6 (0.1) 18 (0.4)
18.5 - <25 1012 (19.7) 136.0 ± 19.7 79.3 ± 11.1 927 (18.1) 421 (8.2) 506 (9.9)
25 - <30 1882 (36.7) 140.7 ± 20.3 79.8 ± 11.5 1816 (35.4) 960 (18.7) 856 (16.7)
30 2206 (43.0) 140.2 ± 20.4 78.8 ± 12.2 2168 (42.2) 1113 (21.7) 1055 (20.6)
(Continued )
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for>100.000 € versus <25.000 €, P = 0.0134), and higher proteinuria (OR 0.735 (0.621–0.871)
for albuminuria30300 versus<30 mg/g and OR 0.488 (0.406–0.587) for300 versus <30
mg/g, P<0.0001). In contrast, eGFR strata, education, BMI, ethanol intake and presence of
diabetes mellitus were no longer associated with blood pressure control in the multivariate
analysis.
Also, we analyzed the medication pattern with regard to the control of blood pressure (Fig
5). Patients with controlled hypertension more often used 1–3 antihypertensive medications
Table 1. (Continued)
Patients number
(%)
SBP
(mmHg)
DBP
(mmHg)
Patients with Hypertension
(%)
Uncontrolled
(%)
Controlled
(%)
Smoking status
Non-smoker 2116 (40.9) 139.3 ± 19.6 79.8 ± 11.6 2023 (39.1) 1022 (19.8) 1001 (19.4)
Former smoker 2232 (43.2) 140.5 ± 21.1 78.7 ± 11.8 2161 (41.8) 359 (6.9) 429 (8.3)
Current smoker 822 (15.9) 137.1 ± 20.2 79.2 ± 12.0 788 (15.2) 1141 (22.1) 1020 (19.7)
Alcohol intake
No or very little 4173 (81.0) 138.8 ± 20.5 79.6 ± 11.8 4006 (77.7) 1982 (38.4) 2024 (39.3)
Moderate or high 982 (19.0) 142.1 ± 19.4 79.7 ± 11.5 951 (18.4) 529 (10.3) 422 (8.2)
Cardiovascular disease
No 3517 (67.9) 138.8 ± 19.9 80.7 ± 11.5 3341 (64.5) 1677 (32.4) 1664 (32.1)
Yes 1666 (32.1) 140.9 ± 21.2 76.2 ± 11.7 1644 (31.7) 852 (31.7) 792 (31.7)
Cerebrovascular disease
No 4680 (90.3) 139.3 ± 20.2 79.6 ± 11.7 4488 (86.6) 2264 (43.7) 2224 (42.9)
Yes 503 (9.7) 141.7 ± 21.5 76.6 ± 12.3 497 (9.6) 265 (5.1) 232 (4.5)
Peripheral vascular disease
No 4695 (90.6) 139.1 ± 20.3 79.7 ± 11.7 4507 (87.0) 2255 (43.5) 2252 (43.4)
Yes 488 (9.4) 143.2 ± 20.8 75.4 ± 11.3 478 (9.2) 274 (5.3) 204 (3.9)
The frequency of the respective strata for the analyzed variables is indicated for all participants, participants with hypertension, hypertensive participants with
uncontrolled hypertension (140/90 mmHg), and participants with controlled hypertension (<140/90 mmHg). The percentage numbers (in brackets) indicate percent
of all participants in which the respective variable was known. SBP = Systolic blood pressure, DBP = Diastolic blood pressure.
https://doi.org/10.1371/journal.pone.0202604.t001
Fig 2. Awareness of hypertension according to control of hypertension and medication pattern.
https://doi.org/10.1371/journal.pone.0202604.g002
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Table 2. Use of antihypertensive medications.
Patients with hypertension (%) Uncontrolled Controlled
Antihypertensive Medication
Yes 4858 (97.4) 2402 (95.0) 2456 (100.0)
No 127 (2.6) 127 (5.0) 0 (0.0)
Antihypertensive medication sorted by substance class
RAS inhibitors (total) 4134 (82.9) 2026 (80.1) 2108 (85.9)
ACE inhibitors 2439 (48.9) 1140 (45.1) 1299 (52.9)
Angiotensin receptor blocker 2011 (40.3) 1031 (40.8) 980 (39.9)
Renin inhibitors 285 (5.7) 176 (6.9) 109 (4.4)
Combined RAS blockade (total) 585 (11.7) 313 (12.4) 272 (11.1)
ACEI and ARB 396 (7.9) 197 (7.8) 199 (8.1)
ACEI and renin inhibitor 84 (1.7) 48 (1.9) 36 (1.5)
ARB and renin inhibitor 105 (2.1) 68 (2.7) 37 (1.5)
ACEI, ARB and renin inhibitor 16 (0.3) 8 (0.3) 8 (0.3)
Beta blocker 2844 (57.1) 1474 (58.3) 1370 (55.8)
Vasodilator 219 (4.4) 114 (4.5) 105 (4.3)
Ca channel blocker 1951 (39.1) 1088 (43.0) 863 (35.1)
Central Antiadrenergic 627 (12.6) 403 (15.9) 224 (9.1)
Peripheral Antiadrenergic 327 (6.6) 215 (8.5) 112 (4.6)
Diuretics (total) 3119 (62.6) 1546 (61.1) 1573 (64.1)
Loop diuretic 1988 (39.9) 966 (38.2) 1022 (41.6)
Thiazides and analogs 1564 (31.4) 803 (31.8) 761 (30.1)
Potassium-sparing diuretics 501 (10.1) 200 (7.9) 301 (12.3)
Usage of a given drug class in percent was calculated in relation to all hypertensive patients, all hypertensive patients with uncontrolled blood pressure (140/90
mmHg), and all hypertensive patients with controlled blood pressure (<140/90 mmHg), respectively. RAS, renin-angiotensin system. ACEI, angiotensin converting
enzyme inhibitors. ARB, angiotensin receptor blockers. RI, renin inhibitor. Ca, Calcium.
https://doi.org/10.1371/journal.pone.0202604.t002
Fig 3. Control of blood pressure in hypertensive participants of the GCKD study.
https://doi.org/10.1371/journal.pone.0202604.g003
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than patients with uncontrolled hypertension. In contrast, patients with uncontrolled hyper-
tension more often used 4 or more different antihypertensive medications than patients with
controlled hypertension. Of the 2529 patients with uncontrolled hypertension, 1291 (51.0%)
met the criteria for resistant hypertension (3 or more different antihypertensive medications
including a diuretic). The multivariate logistic regression for control of blood pressure accord-
ing to the medications used (Table 3) showed that RAS inhibitors and diuretics were associated
with a better chance of control whereas alpha blockers and central sympatholytic agents
appeared to be associated with a poorer chance of control.
Discussion
This cross-sectional analysis of a large cohort of CKD patients under nephrology specialist
care in Germany confirmed the near universal prevalence of hypertension in CKD patients.
Despite very high rates of hypertension awareness and treatment, the latter mostly employing
combination pharmacotherapy with several antihypertensive drugs, the control of hyperten-
sion was disappointing: Only 49.3% of our patients reached the conservative blood pressure
goal of< 140/90 mmHg. Analysis of medication patterns indicated that 51.0% of patients with
uncontrolled blood pressure (i.e. one quarter of the study population) met the criteria for resis-
tant hypertension.
The very high prevalence of hypertension in CKD is not unexpected and in agreement with
previous reports from similar cohorts of CKD patients in high-income countries, e.g. Japan
[19], Spain [16], the U.K. [15], and the U.S. [13]. Although some sociodemographic factors
and comorbidities were associated with prevalence rates of uncontrolled hypertension in a sta-
tistically significant manner, these effects were generally small, and even the sub-groups with a
lower prevalence of hypertension still exhibited a prevalence of uncontrolled hypertension of
90% or more. While unawareness of hypertension is a well-known obstacle for blood pressure
control in the general population, rates of hypertension awareness and treatment were high in
the present cohort, as reported in other CKD cohorts [13, 16, 20]. This observation renders the
relatively low percentage of patients with controlled blood pressure all the more disappointing.
Rates of control of blood pressure in CKD cohorts vary widely. For example, the investiga-
tors of the U.S. Chronic Renal Insufficiency Cohort (CRIC) study reported that 67.1% of their
Fig 4. Frequency distribution of diastolic blood pressure levels of the 1596 patients with uncontrolled systolic but controlled
diastolic blood pressure.
https://doi.org/10.1371/journal.pone.0202604.g004
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Table 3. Association of blood pressure control with demographic, biometric, pharmacologic and other factors.
Univariate analysis Multivariate analysis
Variable OR (95% CI) p-value OR (95% CI) p-value
Age
 18 - < 45 Reference < .0001 Reference < .0001
 45 - < 65 0.511 (0.422–0.621) 0.532 (0.411–0.690)
 65 0.391 (0.323–0.474) 0.379 (0.285–0.505)
Sex
male Reference < .0001 Reference < .0001
female 1.475 (1.315–1.654) 1.424 (1.208–1.678)
Diabetes mellitus
No Reference 0.0003 Reference 0.5734
Yes 0.807 (0.719–0.906) 0.938 (0.799–1.101)
eGFR (ml/min/1.73m2)
 60 Reference 0.0419 Reference 0.8034
 45 - < 60 0.726 (0.621–0.849) 0.962 (0.725–1.276)
 30 - < 45 0.790 (0.677–0.921) 0.882 (0.722–1.078)
< 30 0.810 (0.649–1.010) 0.791 (0.645–0.969)
Albuminuria (mg/g)
< 30 Reference < .0001 Reference < .0001
 30 - < 300 0.778 (0.680–0.891) 0.735 (0.621–0.871)
 300 0.632 (0.552–0.725) 0.488 (0.406–0.587)
Marital status
Married Reference 0.1975 Reference 0.7603
Single 1.323 (1.089–1.609) 1.122 (0.862–1.459)
Separated/divorced 1.144 (0.919–1.424) 1.067 (0.808–1.409)
Widowed 0.938 (0.751–1.172) 0.939 (0.703–1.256)
Education level
Low Reference 0.0018 Reference 0.7746
Intermediate 1.200 (1.053–1.367) 1.064 (0.898–1.260)
High 1.231 (1.053–1.440) 1.011 (0.818–1.249)
other 1.242 (0.835–1.849) 0.950 (0.571–1.582)
Annual gross income
< 25.000 € Reference < .0001 Reference 0.0134
25.000–50.000 € 1.303 (1.129–1.503) 1.273 (1.082–1.498)
50.000–100.000 € 1.373 (1.124–1.678) 1.286 (1.011–1.636)
> 100.000 € 1.653 (1.038–2.632) 1.635 (0.968–2.762)
Insurance status
Statutory Reference 0.5781 Reference 0.6973
Private 1.078 (0.865–1.342) 1.081 (0.824–1.418)
unkown 0.517 (0.047–5.709) 0.616 (0.053–7.116)
Body mass index
18.5 - <25 Reference 0.0050 Reference 0.0716
<18.5 2.490 (0.980–6.327) 2.320 (0.723–7.451)
25 - <30 0.742 (0.632–0.870) 0.851 (0.693–1.045)
30 0.789 (0.676–0.920) 0.859 (0.696–1.060)
Smoking status
(Continued)
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patients had blood pressure levels < 140/90 mmHg [13]. In contrast, a large cohort of CKD
patients in a different setting in the U.S. described blood pressure control < 140/90 mmHg in
only 11–21% of the patients (depending on CKD stage) [20]. In another CKD cohort derived
from the U.S. National Health and Nutrition Examination Survey 1996–2006, 48.5% of the
participants exhibited controlled blood pressure (defined as blood pressure < 140/90 mmHg)
[21]. A cross-sectional survey of CKD patients in Spain found blood pressure levels < 140/90
mmHg in 45.5% of participants [22]. Different inclusion criteria with regard to CKD stages or
different settings for recruitment, visits and blood pressure measurements may contribute to
the varying control rates.
Within our study higher age and male sex were associated with lower odds for a successful
control of hypertension, as also described in other studies of CKD patients [13, 20, 23]. The
eGFR stratum (or the CKD stage, conversely) did not affect the odds for control of hyperten-
sion after adjustment for other variables, as also reported from the CRIC study [13]. Other
authors [20], however, reported conflicting findings. Of particular concern is the lower control
rate in patients with higher proteinuria in our and several other reports [13, 22, 23], because
Table 3. (Continued)
Univariate analysis Multivariate analysis
Variable OR (95% CI) p-value OR (95% CI) p-value
Non smoker Reference 0.1296 Reference 0.7656
Former smoker 0.913 (0.808–1.030) 1.296 (1.046–1.606)
Current smoker 1.220 (1.034–1.439) 1.041 (0.888–1.221)
Alcohol intake
No or very little Reference 0.0007 Reference 0.9754
Moderate or high 0.781 (0.678–0.900) 1.004 (0.837–1.204)
Cardivascular disease
No Reference 0.2792 Reference 0.0042
Yes 0.937 (0.832–1.054) 1.343 (1.093–1.650)
Cerebrovascular disease
No Reference 0.2248 Reference 0.5527
Yes 0.891 (0.740–1.073) 0.924 (0.706–1.211)
Peripheral vascular disease
No Reference 0.0025 Reference 0.0072
Yes 0.746 (0.616–0.902) 0.695 (0.529–0.912)
Antihypertensive Medication
Reference Reference
RAS inhibitors (ACEI, or ARB or RI) 1.504 (1.295–1.747) < .0001 1.617 (1.335–1.960) < .0001
Beta blocker 0.903 (0.807–1.010) 0.0745 0.963 (0.827–1.122) 0.5326
Ca channel blocker 0.718 (0.640–0.804) < .0001 0.892 (0.767–1.038) 0.1374
Vasodilator 0.946 (0.721–1.241) 0.6892 0.937 (0.664–1.324) 0.7602
Central Antiadrenergic 0.529 (0.445–0.630) < .0001 0.678 (0.542–0.848) 0.0006
Peripheral Antiadrenergic 0.514 (0.406–0.651) < .0001 0.614 (0.456–0.825) 0.0013
Diuretics (total) 1.133 (1.010–1.270) 0.0336 1.460 (1.245–1.712) < .0001
Data indicate the odds ratio for a successful control of blood pressure among hypertensive patients. Ninety-five % confidence intervals (CI) are shown in brackets. The
results of univariate analyses are shown in columns 2 and 3, and the results of the multivariate analysis in columns 4 and 5.
 indicates that for the antihypertensive medications, the Reference population comprised all hypertensive patients not treated with the respective antihypertensive drug
class.
https://doi.org/10.1371/journal.pone.0202604.t003
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these are the very patients who would presumably benefit most from a good control of blood
pressure [5]. Somewhat surprising to us was the clear and strong association of higher self-
declared yearly gross income with better control of blood pressure. The association by itself
was not unexpected, as described e.g. in the CRIC study [13], but the relationship was clearly
more marked as in CRIC, despite Germany’s mandatory universal health insurance [24].
Please note that there were a significant number of patients for which we did not have infor-
mation on annual gross income. We assume that some patients did not feel comfortable to
reveal their level of income. All patients had access to nephrology specialist care (GCKD inclu-
sion criterium) and blood pressure medications are provided at no costs or for small copay-
ments. In Germany, the public discussion about differential access to health services has for
years revolved around the type of health insurance (statutory insurance for most of the popula-
tion versus private insurance for ~ 10%, mostly higher-income persons) [24]. In this regard, it
appears to be of note that the type of insurance (statutory versus private) did not affect the
odds for control of blood pressure but income still did.
As awareness of hypertension and rates of pharmacological treatment were high, we investi-
gated whether a high prevalence of treatment-resistant hypertension in our CKD patients may
account for the low overall rates of controlled blood pressure. Our data show that approxi-
mately half of our patients with uncontrolled blood pressure had resistant hypertension. We
used criteria for resistant hypertension adapted from the definition in the 2013 European Soci-
ety of Hypertension / European Society of Cardiology hypertension guidelines [11]: blood
pressure 140 mmHg systolic or 90 mmHg diastolic despite at least 3 different antihyperten-
sive medications, including a diuretic. A recent report from the CRIC study used a slightly dif-
ferent definition of “apparent treatment resistant hypertension” and demonstrated that
resistant hypertension at enrolment was associated with increased mortality as well as elevated
risks for cardiovascular and renal events [25].
An important limitation of our study is that we collected information on the prescribed
medications but not on the drug doses, intake schedules, or duration of treatment. Since we
also did not assess the adherence to treatment, which is difficult to measure [26], we cannot
exclude that the actual drug intake may markedly fall short of the number of drugs prescribed
[27]. A previous questionnaire-based estimate of the adherence indicated that patients with
CKD exhibited no better adherence regarding antihypertensive medications than hypertensive
Fig 5. Number of different antihypertensive medications in patients with controlled or uncontrolled hypertension.
https://doi.org/10.1371/journal.pone.0202604.g005
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patients without CKD [28]. Others have reported lower adherence with worsening GFR [29].
On the other hand it is important to note that information on medication intake was directly
obtained from patients during standardized interviews rather than from prescription informa-
tion in health records or from the treating physicians, which may have reduced differences
between medication information and actual intake. Nevertheless, our estimate of the frequency
of resistant hypertension is likely to be biased by nonadherence [30].
Conversely, our results indicate that 49.0% of the patients with uncontrolled hypertension
did not meet the definition of resistant hypertension. While this implies that there was room
for use of more anti-hypertensive agents, the overall anti-hypertensive medication use was
already substantial. More than 80% of the hypertensive patients received RAS inhibitors, as
recommended by many guidelines [10, 11]. The relatively high percentage of patients receiving
aliskiren and/or double RAS blockade is probably due to the fact that the data were collected
before the publication of the results of the ALTITUDE [31] and VA-NEPHRON-D [32] trials
which cautioned against double RAS blockade. The frequency of use of RAS inhibitors as well
as of other antihypertensive drug classes was broadly similar to the respective frequencies in
CKD cohort studies from Spain [16] and the U.S. [13]. In contrast, a survey-based study of
CKD patients identified from the U.S. National Health and Nutrition Examination Survey
reported far lower frequencies of RAS blocker usage [33], suggesting that the prescription of
these drugs is associated with nephrology care. In our study as well as in CRIC [13], use of
RAS inhibitors was associated with better odds for blood pressure control. Several infrequently
used drug classes were associated with a lower odds ratio for blood pressure control but this
should not be misunderstood to imply a causal relationship. Presumably these drugs were
mostly employed as third-line agents in patients with otherwise poorly controlled hyperten-
sion. Diuretics were used with similar frequencies in the CRIC cohort [13] and in patients
from the GCKD study, and were associated with better control of blood pressure. Again, this
observation should not be construed to imply a cause-and-effect relationship; the design of
our study does not permit such a conclusion.
A further limitation of our study is the use of office blood pressure measurements obtained
during a single visit, even though they were obtained in a highly standardized way. A study
which compared office and 24 hour ambulatory blood pressure measurements in CKD
patients from a large registry in Spain recorded disagreement between both measurements in a
third of the patients [34]. Similar results were recently reported from the CRIC study: only
4.1% of patients had controlled 24-hour ambulatory blood pressure but uncontrolled office
blood pressure, i.e. “white-coat” hypertension, whereas no fewer than 27.8% exhibited
“masked” hypertension, i.e. uncontrolled ambulatory blood pressure despite controlled office
blood pressure [35]. In light of these recent data, we speculate that the control of blood pres-
sure in our patients may be even worse than our office blood pressure results would imply.
In summary, our data clearly show that blood pressure control of CKD patients remains
challenging even in the setting of nephrology specialist care, despite high rates of awareness
and medication use. The fact that our observations are very similar to those in CRIC, a large,
multi-ethnic cohort in the U.S. where patients were enrolled in large centers rather than small
practices, indicates that this challenge exists independent of ethnicity, differences in environ-
mental factors, health care coverage and treatment settings. Given that poorly controlled blood
pressure is closely associated with progression of kidney disease as well as cardiovascular com-
plications, intensified efforts to control blood pressure appear warranted.
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